Prelude Therapeutics (PRLD) investor relations material

Core competencies and portfolio strategy

• Focus on addressing unmet needs in cancer treatment drives capability development and portfolio construction.

• Emphasis on designing differentiated molecules across multiple target classes, not limited by modality.

• Portfolio opportunities evaluated by patient need, strength of evidence, and target candidate profile.

• Business development prioritizes strategic collaborations to accelerate patient access.

• Operates as a fully integrated biopharmaceutical company, aiming to bring discoveries to market.

KAT6 program insights

• KAT6A is a validated oncology target, especially in ER-positive breast cancer, with amplification in 12–15% of cases.

• Selective KAT6A degradation aims to improve efficacy and reduce bone marrow toxicity compared to dual KAT6A/B inhibition.

• Preclinical data show strong efficacy and minimal neutrophil impact at effective doses.

• Benchmarking against Pfizer’s dual inhibitor demonstrates superior tumor regression and safety profile.

• Clinical development will focus on monotherapy safety and efficacy, followed by combination with CDK4/6 inhibitors.

Clinical development plans and market opportunity

• Initial clinical studies will start at pharmacologically active doses, with dose escalation and biomarker analysis.

• Proof-of-concept data expected by the second half of 2027, with safety readouts anticipated early in trials.

• Success in combinations could unlock significant commercial opportunities, especially in newly diagnosed and adjuvant settings.

• The evolving breast cancer landscape is monitored, including less selective compounds and new targets.